ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1005

Renal Protective Treatment Use for Non-Diabetic CKD in Japan, Sweden, and the United States

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Tangri, Navdeep, University of Manitoba Max Rady College of Medicine, Winnipeg, Manitoba, Canada
  • Svensson, Maria K., Department of Medical Sciences, Renal Medicine, Uppsala University, Uppsala, Sweden
  • Bodegard, Johan, CVRM Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
  • Adamsson Eryd, Samuel, CVRM Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
  • Thuresson, Marcus, Statisticon AB, Uppsala, Sweden
  • Sofue, Tadashi, Department of Cardiorenal and Cerebrovascular Medicine, Kagawa University, Kagawa, Japan

Chronic kidney disease (CKD) is an underdiagnosed disease affecting 10% of people worldwide. Appropriate management of CKD delays progression and reduces its burden. Renin–angiotensin system inhibitors (RASis) have been the mainstay of CKD treatment until recently. Here we describe the use of RASis and the sodium–glucose co-transporter-2 inhibitor dapagliflozin in a contemporary population of patients with CKD.


This study used secondary data extracted from electronic health records or claims data sources. Adult patients with CKD (either two estimated glomerular filtration rate [eGFR] measurements ≥ 90 days apart of which both were ≤ 60 mL/min/1.73 m2 or an eGFR ≤ 60 mL/min/1.73 m2 followed by a CKD diagnosis) who were new RASi or dapagliflozin users during 2021–2023 were included. Patients with type 1 or gestational diabetes, stage 5 CKD or on dialysis were excluded. RASi and dapagliflozin doses and persistence were assessed in the year following initiation.


Overall, 159 220 patients were included (Japan, 57 222; Sweden, 10 861; USA, 91 137). Median ages were 75, 72 and 72 years, and 63%, 66% and 52% were males in Japan, Sweden and the USA, respectively. Of patients without type 2 diabetes, a high proportion receiving dapagliflozin remained on the evidence-based 10 mg target dose (Figure). A large proportion of patients treated with RASis received low doses. At 12-month follow-up, dapagliflozin persistence was approximately 65%, 80% and 55% in Japan, Sweden and the USA, respectively, and was 34%, 75% and 64% for RASi, respectively.


CKD treatment with dapagliflozin was associated with a high likelihood of receiving and remaining on target dose compared with RASi treatment. Efforts to maintain patients on renal protective treatment are needed.


  • Commercial Support – AstraZeneca